R&D Collaboration with MNC

Background

The Company:
HT
HT BioImaging is a revolutionary patented medical imaging Startup. Our goal is to detect and classify cancer early on the spot. Our exceptional team includes AI, signal analysis and computer vision experts, heat transfer & thermodynamics top researchers, oncologists, radiologists, and one successful serial entrepreneur.

The Foreign Partner:
IBM

International Business Machines Corporation is an American multinational technology company headquartered in Armonk, New York.

Successful Innovation

HT BioImaging is developing medical imaging technology for the detection and mapping of cancerous tissues at the point of care and operating rooms, using the tissue heat diffusion properties. With the help of the IIA MNC’s program, a partnership has been established with IBM Corporation that allowed the company to move its unique database to the cloud and increase the efficiency of testing and analysis which was necessary for R&D and clinical trial progress.

In this collaboration program, the company has developed AI algorithms on top of the IBM Cloud infrastructure, accompanied by the technical team of IBM Israel. The cloud infrastructures have replaced a computer attached to the imaging facility, enabled to use a large database, run complex algorithms in a short time and high level of accuracy and efficiency.

"The project was successful - and greatly promoted the development of algorithms in the company. The move to cloud-based analytics has enabled the company to deliver significant results, quickly, efficiently analyze information, as well as manage and control the company’s database - which will support the business model and readiness of HT Bioimaging to the market. In addition, in 2019 the company engaged in research collaboration in a clinical trial with a large U.S. hospital and as a result, increased its database and significantly improved its algorithm accuracy to over 90% accuracy in oral cancer detection.
The company also recruited two new employees to the company staff, two new investors were recruited, and an agreement was signed with a strategic partner. A first article will be published soon showing the results of the experiment and more announcements are expected by the end of 2020."
Shani Toledano,
Co-Founder & CEO, HT BioImaging